Time, Money, Life
Contract the time line, Differentiated, Unmet needs for ALL
This page includes recent “The Lattice®” podcast interviews with our speakers, press release from attending companies, and more media for you to get to know our unique proposition to healthcare.
-
What if lifesaving antibodies could be made without relying on millions of liters of donor plasma? We sit down with Lyric Bio’s co‑founders, immunologist and bioprinting pioneer Melanie Mathieu and biotech operator Kevin “Kayj” Shannon, to unpack how tissue‑engineered bioreactors could turn IVIG from a scarce, rationed therapy into an affordable, abundant standard of care. Their thesis is bold: recreate the right human tissue niche in vitro, unlock massive cell density and physiological function, and you can manufacture complex therapeutics at a fraction of today’s cost.
-
-
In this episode, Alyssa Huffman, CEO and co-founder of Allumin8, shares the six-year journey behind a first-of-its-kind 5.5 mm porous, 3D-printed pedicle screw. We discussed how Allumin8 earned FDA clearance and why design details matter for fatigue, fixation, and fewer revisions. We also map a path toward “therapeutic hardware” that integrates orthobiologics without slowing surgeons down. Join us as we explore the challenges, triumphs, and vision behind Allumin8’s mission to change lives.
-
-
In this episode, Dr. Karolina Valente and I discuss advancements in bioprinting technology, with a particular focus on VoxCell’s high-resolution bioprinting technologies and its unique business approaches. She explains how these innovations enable the creation of better types of 3D human tissue structures with intricate blood vessel networks. The conversation also explores the potential applications of these 3D tissues in the drug discovery process for biopharmaceutical companies, as well as lessons and insights from leading a cutting-edge biotech startup as a scientific founder. I have learned a lot from Karolina, and I hope you can too.
Read full show notes.
-
Canadian biotech company secures major collaborations with Altasciences, ValiRx, and BC Cancer as pharmaceutical industry embraces human-relevant drug development models (Click to Read More)
-
How well do we really understand the body? For decades, surgeons have relied on static scans and flat 2D models to plan procedures. Gilly Yildirim believes it’s time to expand our view to more dimensions. As founder and CEO of Vent Creativity, he is bringing together point clouds, digital twins, and physics-based AI to capture movement with a level of precision that static imaging cannot match. In conversation with Jenny Chen, Yildirim describes how his team built a platform that sees the body not as a collection of bones, but as a dynamic system of forces and interactions. Their software models the physics of ligaments, cartilage, and bone to predict how a patient’s knee will behave before surgery even begins. The goal is to give surgeons a clearer and reliable picture of what they’re working with.
-
Vent Creativity℠ Receives FDA-Clearance for AI-Powered Digital-Twin Knee Arthroplasty Planning Tool, Hermes. Click to read more.
-
What if 3D printing technology could finally handle the thick, functional materials needed for real-world manufacturing? That’s the question Berlin-based startup Quantica set out to answer—redefining what’s possible with industrial inkjet systems. In this episode of the Lattice Podcast, we sit down with co-founder and co-inventor Ben Hartkopp to explore how Quantica’s revolutionary printhead technology enables additive manufacturing with high-viscosity materials, from medical-grade silicones to conductive adhesives. Designed to overcome the limitations of traditional 3D printers and screen printing methods, their NovoJet system is poised to transform industries such as healthcare, automotive, electronics, and beyond.
Read full show notes.
-
Biotechnology is advancing at an unprecedented rate, and one of the most groundbreaking developments in this field is bioprinting. In our latest podcast episode, we spoke with Mr. Mike Graffeo, CEO and co-founder of Fluoform3D, a startup at the forefront of bioprinting technology emerging from Carnegie Mellon University. With a focus on creating sophisticated tissue structures using what’s known as FRESH Technology, Fluoform3D is not just reshaping scientific inquiry—it’s redefining possibilities in medical therapeutics. The podcast begins with Mike detailing the remarkable journey of Fluoform3D, founded in 2018 when he and his co-founders sought to bring innovative bioprinting solutions from the lab into real-world applications. Their core mission is to address the urgent need for replacement tissues and organs, a problem that has long plagued the medical field.
Read full show notes.
-
FluidForm Bio™ Announces Advance in Bioprinted Tissue Therapies with Landmark Publication in Science Advances (Read more)
FluidForm Bio™ Presents Six-Month Efficacy Data of FRESH 3D Bioprinted Human Islet Subcutaneous Scaffolds at the American Diabetes Association (ADA) 85th Scientific Sessions (Read more)
